Empagliflozin Is Not Renoprotective in Non-Diabetic Rat Models of Chronic Kidney Disease
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985823%3A_____%2F22%3A00563725" target="_blank" >RIV/67985823:_____/22:00563725 - isvavai.cz</a>
Alternative codes found
RIV/00023001:_____/22:00083478 RIV/00216208:11120/22:43924106
Result on the web
<a href="https://www.mdpi.com/2227-9059/10/10/2509" target="_blank" >https://www.mdpi.com/2227-9059/10/10/2509</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/biomedicines10102509" target="_blank" >10.3390/biomedicines10102509</a>
Alternative languages
Result language
angličtina
Original language name
Empagliflozin Is Not Renoprotective in Non-Diabetic Rat Models of Chronic Kidney Disease
Original language description
Gliflozins (sodium-glucose transporter-2 inhibitors) exhibited renoprotective effects not only in diabetic but also in non-diabetic patients with chronic kidney disease (CKD). Controversial results were reported in experimental non-diabetic models of CKD. Therefore, we examined empagliflozin effects in three CKD models, namely, in fawn-hooded hypertensive (FHH) rats, uninephrectomized salt-loaded (UNX + HS) rats, and in rats with Goldblatt hypertension (two-kidney, one-clip 2K1C) that were either untreated or treated with empagliflozin (10 mg/kg/day) for eight weeks. Plethysmography blood pressure (BP) was recorded weekly, and renal parameters (proteinuria, plasma urea, creatinine clearance, and sodium excretion) were analyzed three times during the experiment. At the end of the study, blood pressure was also measured directly. Markers of oxidative stress (TBARS) and inflammation (MCP-1) were analyzed in kidney and plasma, respectively. Body weight and visceral adiposity were reduced by empagliflozin in FHH rats, without a significant effect on BP. Experimentally induced CKD (UNX + HS and 2K1C) was associated with a substantial increase in BP and relative heart and kidney weights. Empagliflozin influenced neither visceral adiposity nor BP in these two models. Although empagliflozin increased sodium excretion, suggesting effective SGLT-2 inhibition, it did not affect diuresis in any experimental model. Unexpectedly, empagliflozin did not provide renoprotection because proteinuria, plasma urea, and plasma creatinine were not lowered by empagliflozin treatment in all three CKD models. In line with these results, empagliflozin treatment did not decrease TBARS or MCP-1 levels in either model. In conclusion, empagliflozin did not provide the expected beneficial effects on kidney function in experimental models of CKD.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30105 - Physiology (including cytology)
Result continuities
Project
<a href="/en/project/GA19-06199S" target="_blank" >GA19-06199S: Complex analysis of protective actions of empagliflozin on metabolic parameters and cardiorenal damage in experimental non-diabetic hypertension</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Biomedicines
ISSN
2227-9059
e-ISSN
2227-9059
Volume of the periodical
10
Issue of the periodical within the volume
10
Country of publishing house
CH - SWITZERLAND
Number of pages
14
Pages from-to
2509
UT code for WoS article
000872279500001
EID of the result in the Scopus database
2-s2.0-85140611804